Evaluation of the efficiency of peptide receptor radionuclide therapy in patients with metastatic prostate carcinoma: A protocol for systematic review and meta-analysis

BACKGROUND: Metastatic prostate carcinoma has poor prognoses with a median survival period ranging from 2 to 5 years with existing therapeutic challenges. Currently, peptide receptor radionuclide therapy is permitted as a treatment method for metastatic prostate carcinoma patients. Therefore, it is...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Gang, Tang, Tang, Liu, Xiao-Peng, Zhou, Zhong-Hua, Li, Feng-Jiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084079/
https://www.ncbi.nlm.nih.gov/pubmed/33907113
http://dx.doi.org/10.1097/MD.0000000000025612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084079/
https://www.ncbi.nlm.nih.gov/pubmed/33907113
http://dx.doi.org/10.1097/MD.0000000000025612

Ejemplares similares